Lilly’s Omvoh Maintains Ulcerative Colitis Clearance Through Four Years

Eli Lilly and Company released long-term data for its ulcerative colitis treatment, Omvoh (mirikizumab-mrkz).

The LUCENT-3 open-label extension study tracked patients over four years of continuous therapy. Data shows 63.5% of patients who achieved disease clearance at one year maintained that status through year four.

Omvoh is the first and only IL-23p19 inhibitor to demonstrate this level of durable disease clearance. The four-year safety profile remained consistent with previous clinical observations. No new safety concerns were identified.